Search Results

Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9

Authors: Koronyo-Hamaoui, Maya; Ko, MinHee K.; Koronyo, Yosef; Azoulay, David; Seksenyan, Akop; Kunis, Gilad; Pham, Michael; Bakhsheshian, Joshua; Rogeri, Patricia; Black, Keith L.; Farkas, Daniel L.; Schwartz, Michal

Source: Journal of Neurochemistry, Volume 111, Number 6, December 2009 , pp. 1409-1424(16)

Publisher: Blackwell Publishing

Zn²⁺ mediates ischemia-induced impairment of the ubiquitin-proteasome system in the rat hippocampus

Authors: Chen, Min; Chen, Qian; Cheng, Xue-Wen; Lu, Ting-Jia; Liu, Han-Xing; Jia, Jie-Min; Zhang, Chi; Xu, Li; Xiong, Zhi-Qi

Source: Journal of Neurochemistry, Volume 111, Number 5, December 2009 , pp. 1094-1103(10)

Publisher: Blackwell Publishing

Regulation of PINK1 by NR2B-containing NMDA receptors in ischemic neuronal injury

Authors: Shan, Yuexin; Liu, Baosong; Li, Lijun; Chang, Ning; Li, Lei; Wang, Hanbin; Wang, Dianshi; Feng, Hua; Cheung, Carol; Liao, Mingxia; Cui, Tianyuan; Sugita, Shuzo; Wan, Qi

Source: Journal of Neurochemistry, Volume 111, Number 5, December 2009 , pp. 1149-1160(12)

Publisher: Blackwell Publishing

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy

Authors: Zemlyak, Ilona; Manley, Nathan; Vulih-Shultzman, Inna; Cutler, Andrew B.; Graber, Kevin; Sapolsky, Robert M.; Gozes, Illana

Source: Journal of Neurochemistry, Volume 111, Number 5, December 2009 , pp. 1252-1263(12)

Publisher: Blackwell Publishing

Cannabinoids and Parkinson's Disease

Authors: Garcia-Arencibia, Moises; Garcia, Concepcion; Fernandez-Ruiz, Javier

Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets, Volume 8, Number 6, December 2009 , pp. 432-439(8)

Publisher: Bentham Science Publishers

Glutamate Receptors as Therapeutic Targets for Parkinson's Disease

Authors: Johnson, Kari A.; Conn, P. J.; Niswender, Colleen M.

Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets, Volume 8, Number 6, December 2009 , pp. 475-491(17)

Publisher: Bentham Science Publishers

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

Authors: Katrych, Oleksandra; Simone, Tessa M.; Azad, Shara; Mousa, Shaker A.

Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets, Volume 8, Number 6, December 2009 , pp. 512-519(8)

Publisher: Bentham Science Publishers

Cannabinoids, multiple sclerosis and neuroprotection

Authors: de Lago, Eva; Gómez-Ruiz, María; Moreno-Martet, Miguel; Fernández-Ruiz, Javier

Source: Expert Review of Clinical Pharmacology, Volume 2, Number 6, November 2009 , pp. 645-660(16)

Publisher: Expert Reviews

Activated astrocytes: a therapeutic target in Alzheimer's disease?

Authors: Fuller, Stacey; Münch, Gerald; Steele, Megan

Source: Expert Review of Neurotherapeutics, Volume 9, Number 11, November 2009 , pp. 1585-1594(10)

Publisher: Expert Reviews

Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors: Rezai-Zadeh, Kavon; Gate, David; Szekely, Christine A; Town, Terrence

Source: Expert Review of Neurotherapeutics, Volume 9, Number 11, November 2009 , pp. 1623-1633(11)

Publisher: Expert Reviews

What is the association between depression and Alzheimer's disease?

Authors: Tsuno, Norifumi; Homma, Akira

Source: Expert Review of Neurotherapeutics, Volume 9, Number 11, November 2009 , pp. 1667-1676(10)

Publisher: Expert Reviews

Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?

Authors: Muresan, Virgil; Muresan, Zoia

Source: Future Neurology, Volume 4, Number 6, November 2009 , pp. 761-773(13)

Publisher: Future Medicine

Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?

Authors: Muresan, Virgil; Muresan, Zoia

Source: Future Neurology, Volume 4, Number 6, November 2009 , pp. 761-773(13)

Publisher: Future Medicine

Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome

Authors: Galloway, Jocelyn N; Nelson, David L

Source: Future Neurology, Volume 4, Number 6, November 2009 , pp. 785-798(14)

Publisher: Future Medicine

Pharmacological Targeting of the Hsp70 Chaperone

Authors: Patury, Srikanth; Miyata, Yoshinari; Gestwicki, Jason E.

Source: Current Topics in Medicinal Chemistry, Volume 9, Number 15, November 2009 , pp. 1337-1351(15)

Publisher: Bentham Science Publishers

Purine-Scaffold Hsp90 Inhibitors

Authors: Taldone, Tony; Chiosis, Gabriela

Source: Current Topics in Medicinal Chemistry, Volume 9, Number 15, November 2009 , pp. 1436-1446(11)

Publisher: Bentham Science Publishers

Dysfunction of the unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition

Authors: Paz Gavilán, María; Pintado, Cristina; Gavilán, Elena; Jiménez, Sebastián; Ríos, Rosa M.; Vitorica, Javier; Castaño, Angélica; Ruano, Diego

Source: Aging Cell, Volume 8, Number 6, December 2009 , pp. 654-665(12)

Publisher: Blackwell Publishing

Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme

Authors: Zhai, Rong; Rizzi, Menico; Garavaglia, Silvia

Source: Cellular and Molecular Life Sciences CMLS, Volume 66, Number 17, September 2009 , pp. 2805-2818(14)

Publisher: Springer

Neuroprotection, Neuronal Remodelling, and Anxiety-Like Behavior: The Role of the Teneurin and Teneurin C-Terminal Associated Peptide (TCAP) System in the Hippocampus

Authors: Tan, Laura A.; Lovejoy, David A.

Source: American Journal of Neuroprotection and Neuroregeneration, Volume 1, Number 1, June 2009 , pp. 3-10(8)

Publisher: American Scientific Publishers

Could PKR inhibition modulate human neurodegeneration?

Authors: Hugon, Jacques; Paquet, Claire; Chang, Raymond Chuen-Chung

Source: Expert Review of Neurotherapeutics, Volume 9, Number 10, October 2009 , pp. 1455-1457(3)

Publisher: Expert Reviews